磁流体与长春新碱对系统血液免疫功能影响的实验研究  

Experimental Study on Effects of Magnetic Ferrofluid and Vincristine on Systemic Hematogenic Immunologic Function

作　　者：王莉莉[1] 钱宝华[1] 郭峰[1] 花美仙[1] 

机构地区：[1]第二军医大学长海医院输血科,上海200433

出　　处：《深圳中西医结合杂志》2007年第3期129-132,139,共5页Shenzhen Journal of Integrated Traditional Chinese and Western Medicine

基　　金：国家自然科学基金资助项目(30671940)

摘　　要：目的:用体外自然实验体系对纳米级FeO磁流体和抗癌药物长春新碱(VCR)体外对系统血液免疫功能的影响进行分子水平的探讨。方法:采用免疫荧光标记流式细胞仪分析方法,检测血细胞表面相关免疫分子的变化情况。结果:使用纳米级Fe3O4磁流体和抗癌药物VCR以后,自然实验组CD4细胞阳性率(38.87±6.37)%较自然对照组(35.52±6.76)%明显增高(P<0.01),自然实验组白细胞CD55阳性细胞平均荧光强度(68.79±8.98)%较自然对照组(74.78±18.60)%明显降低(P<0.05)。与自然对照组相比CD4分子均表现出一定程度的上调,CD8分子均表现出一定程度的下调。结论:VCR(0.2g/mL)和纳米级Fe3O4磁流体对血细胞的免疫功能都没有不良影响,甚至磁流体还可以提高血液免疫反应中白细胞的免疫功能,为红细胞包载磁流体和抗癌药物治疗肿瘤提供实验依据,为抗癌药红细胞载体靶向抗肿瘤免疫提供新的治疗途径。Objective To research the molecular level effects of Fe3O4 nano-magnetic ferrofluid and anticancer drug vincristine （VCR） on systemic hematogenic immunologic function by means of natural experimental system in vitro. Methods The expression of correlated moleculars on the surface of blood cells were detected and compared using flow cytometry assay. Results The level of CD4 on T cells （38.87±6.37）% in natural experimental group was significantly increased than that of natural control group （35.52±6.76）% （P 〈 0.01）, while the mean fluorescence intensity of CD55 in natural experimental group （68.79±8.98）% was much lower than that of natural control group （74.78 ± 18.60）% （P 〈 0.05）. Compared to natural control group, the expression of CD4 was up-regulated in some degree while CD8 was down-regulated in experimental group. Conclusion VCR （0.2 g/mL） and Fe3O4 nano-magnetic ferrofluid have no harmful effects to hematogenic immunologic function. Magnatic ferrofluid can even elevate the function of leucocytes. The results can supply experimental foundation for erythrocytes to capsulate both magnetic ferrofluid and anticancer drug, and also can provide treatment pathway for anticancer drug erythrocyte carrier targeting antitum or immunity.

关 键 词：红细胞 磁流体 长春新碱 靶向 CD4 CD8 CD55 CD59 

分 类 号：R392.1[医药卫生—免疫学]